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Abstract
Background: Immune reconstitution inflammatory syndrome (IRIS) is a widely recognised complication of antiretroviral
therapy (ART), but there are still limited data from resource-limited settings. Our objective was to characterize the incidence,
clinical spectrum, risk factors and contribution to mortality of IRIS in two urban ART clinics in South Africa.
Methods and Findings: 498 adults initiating ART in Durban, South Africa were followed prospectively for 24 weeks. IRIS
diagnosis was based on consensus expert opinion, and classified by mode of presentation (paradoxical worsening of known
opportunistic infection [OI] or unmasking of subclinical disease). 114 patients (22.9%) developed IRIS (36% paradoxical, 64%
unmasking). Mucocutaneous conditions accounted for 68% of IRIS events, mainly folliculitis, warts, genital ulcers and herpes
zoster. Tuberculosis (TB) accounted for 25% of IRIS events. 18/135 (13.3%) patients with major pre-ART OIs (e.g. TB,
cryptococcosis) developed paradoxical IRIS related to the same OI. Risk factors for this type of IRIS were baseline viral load
.5.5 vs. ,4.5 log10 (adjusted hazard ratio 7.23; 95% confidence interval 1.35–38.76) and #30 vs. .30 days of OI treatment
prior to ART (2.66; 1.16–6.09). Unmasking IRIS related to major OIs occurred in 25/498 patients (5.0%), and risk factors for this
type of IRIS were baseline C-reactive protein $25 vs. ,25 mg/L (2.77; 1.31–5.85), haemoglobin ,10 vs. .12 g/dL (3.36;
1.32–8.52), $10% vs. ,10% weight loss prior to ART (2.31; 1.05–5.11) and mediastinal lymphadenopathy on pre-ART chest
x-ray (9.15; 4.10–20.42). IRIS accounted for 6/25 (24%) deaths, 13/65 (20%) hospitalizations and 10/35 (29%) ART
interruptions or discontinuations.
Conclusion: IRIS occurred in almost one quarter of patients initiating ART, and accounted for one quarter of deaths in the
first 6 months. Priority strategies to reduce IRIS-associated morbidity and mortality in ART programmes include earlier ART
initiation before onset of advanced immunodeficiency, improved pre-ART screening for TB and cryptococcal infection,
optimization of OI therapy prior to ART initiation, more intensive clinical monitoring in initial weeks of ART, and education of
health care workers and patients about IRIS.
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Introduction
Immune reconstitution inflammatory syndrome (IRIS) or
immune reconstitution disease is a widely recognised phenomenon
that occurs in 10227% of patients initiating antiretroviral therapy
(ART) [1,2,3,4,5,6,7,8]. The syndrome may present in two
different ways: ‘‘paradoxical’’ IRIS, when an opportunistic
infection (OI) diagnosed pre-ART initially responds to treatment
but then deteriorates following ART initiation; or ‘‘unmasking’’
IRIS, where disease that is not clinically apparent prior to ART is
triggered by ART initiation, often with unusual or florid
inflammatory features [1,9] in association with rapid restoration
of pathogen-specific immune responses [10]. The clinical spectrum
is extremely diverse, and IRIS has been reported for at least 25
different infections, 2 tumours and 18 other non-infectious
conditions [11]. Pooled incidence rates of paradoxical IRIS are
17% for tuberculosis (TB) (range 8–45%)
[7,12,13,14,15,16,17,18], 20% for cryptococcosis (range 8–49%)
[7,19], 17% for progressive multifocal leukoencephalopathy [20],
7–31% for Kaposi’s sarcoma (KS) [21,22], and 12% for herpes
zoster [23]. Data on the incidence of unmasking IRIS are limited,
but rates of 1–5% for TB IRIS [1,24,25] and 1–2% for
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e40623
cryptococcal IRIS [19] have been reported from Uganda and
South Africa.
Most studies have examined risk factors for paradoxical and
unmasking IRIS as one entity [1,2,3,5,6,26,27], or for paradoxical
IRIS specific to TB [13,15,16,17,18,28,29], cryptococcosis
[30,31,32] or KS [22]. Patient- and ART-related risk factors include
lower baseline absolute and percentage CD4+ cell count
[1,2,3,6,16,18,26,31], lower baseline haemoglobin or haematocrit
[5,22,27], greater magnitude of CD4+ count increase [6,15,32,33]
or viral load (VL) reduction [3,13,15,22,26,28,30,33] on ART,
and use of a boosted protease inhibitor [26]. Pathogen-related factors
include shorter duration of anti-tuberculous or anti-cryptococcal
therapy prior to ART initiation [13,16,28,29,30,31], extrapul-
monary or disseminated TB [15,17,18,29], higher fungal burden
in cryptococcosis [30,32], higher plasma KS-associated herpes
virus (KSHV) load [22], and higher number of prior OIs [27].
IRIS may be a greater problem in resource-limited settings
(RLS), where there is large scale rollout of ART in populations
with high rates of advanced immunodeficiency and co-morbidity.
There are still limited data on the epidemiology of IRIS from
RLS, and debate as to its programmatic importance, particularly
its contribution to the high early mortality seen in the first year of
ART.
Our objective was to document comprehensively the epidemi-
ology of IRIS, in a large prospective cohort of patients initiating
ART in two typical urban clinics in South Africa, including
incidence, clinical spectrum, risk factors, clinical outcome, and
contribution to hospitalisation and death. We postulated that risk
factors would differ according to IRIS subtype, in particular that
advanced immunodeficiency and duration of OI therapy prior to
ART (as indirect measures of pathogen burden) would be risk
factors for paradoxical OI IRIS, while clinical and laboratory
features consistent with undiagnosed OIs would be risk factors for
unmasking OI IRIS.
Methods
Ethics statement
The study was approved by the University of KwaZulu-Natal
Biomedical Research Ethics Committee in November 2006, ref.
E024/06. All patients were provided with a written and verbal
explanation of the study by bilingual research staff in English and/
or isiZulu (the predominant first language in KwaZulu-Natal), and
gave written informed consent.
Study participants
Adult ($18 years) HIV-1-infected ART naı¨ve patients due to
initiate ART according to 2004 South African national guidelines
(CD4+ count of less than 200 cells/mL or WHO stage 4 disease
[34]) were invited to participate in a prospective observational
cohort study at two clinics (King Edward VIII and RK Khan
Hospitals) in Durban, South Africa between December 2006 and
October 2007. King Edward VIII Hospital serves mainly an urban
population, while RK Khan Hospital serves a more mixed urban
and rural population with of poorer health and socioeconomic
status. The same protocols were applied at both sites. ART
regimens were stavudine and lamivudine with efavirenz or
nevirapine, given with co-trimoxazole prophylaxis (either one
month before or at ART initiation) and multivitamins.
Baseline assessments
All patients underwent pre-ART assessment by English- and
isiZulu-speaking research nurses. Data collected using a standar-
dised questionnaire included detailed current and recent symptom
history (elicited by direct questioning), past medical history, and
brief physical examination. Baseline laboratory investigations were
CD4+ and CD8+ counts (FlowcareTM PLG CD-4 Assay, Beckman
Coulter, Ireland), HIV-1 RNA viral load (VL) (NuclisensH
EASYQ HIV-1 V1.1 Assay, Biomerie`ux, Lyon, France), full
blood count, renal function (creatinine), liver enzymes (aspartate
and alanine transaminase, and bilirubin), albumin, glucose,
hepatitis B surface antigen (AXSYM system v.2, Abbott
Diagnostics, Weisbaden, Germany) and syphilis serology (Rapid
Plasma Reagin with confirmation by Treponema pallidum haemag-
glutination assay). Additional baseline serum and plasma samples
were tested retrospectively at the end of study follow-up for
hepatitis C IgG (ADVIA Centaur, Bayer Diagnostics, New York,
USA), herpes simplex type 2 IgG (HerpeSelect 2 ELISA, Focus
Diagnostics), cryptococcal antigen (CrAg) (semi-quantitative latex
agglutination assay; agglutination titres $1:4 were considered
positive), and C-reactive protein (DXC Beckman). Symptomatic
patients were evaluated further according to clinician judgement
and managed in accordance with South African national guide-
lines [34]. Those with suspected TB were screened with chest x-
ray and sputum examination for acid-fast bacilli, and if positive
received a median of 12 weeks of anti-tuberculous therapy prior to
ART initiation. Cryptococcosis was treated with 2 weeks of
intravenous amphotericin B or high-dose fluconazole, followed by
fluconazole consolidation and maintenance therapy. KS-specific
chemotherapy was not widely available in Durban in 2007.
Follow-up assessment and classification of clinical events
Participants were reviewed after 2, 4, 8, 12, 16, 20 and 24 weeks
of ART using standardised questionnaires, with additional medical
assessments as required, and telephone calls to ascertain events in
patients with missed visits. All clinical events, including episodes of
new or worsening symptoms, hospital admissions, deaths and
changes in ART regimen were recorded. CD4+ and CD8+ counts,
VL, full blood count, liver enzymes, albumin and renal function
were measured at the time of each event, and routinely at 12 and
24 weeks.
All patients with clinical events were evaluated by at least one of
the investigators in person (usually LH), other than in a few cases
where information was obtained from other medical or nursing
staff, medical chart review, or patients’ relatives. All events were
then reviewed by $2 investigators (LH, YM, PE, AM), and the
diagnosis of IRIS established through consensus review, after
consideration of all available clinical and laboratory data.
Indeterminate cases were discussed between all three investigators
and/or a dermatologist (AM).
Events were then categorised into a number of groups: IRIS
(either probable IRIS, where IRIS was the most likely of possible
causes, or possible IRIS, where IRIS was plausible but competing
explanations were equal or stronger in likelihood, or the diagnosis
could not be resolved with available information) or non-IRIS
(includes new infection; drug toxicity; progression of pre-ART
disease; other conditions). We subsequently combined Possible and
non-IRIS into a single non-IRIS category, as the preponderance
of evidence suggested that IRIS was unlikely in these cases.
A detailed description of follow-up procedures and criteria used
for classification of suspected IRIS has been reported previously
[24,35]. In brief, diagnostic criteria for probable IRIS included
relapse, exacerbation or new onset of an infectious or in-
flammatory condition in association with evidence of at least
partial immune recovery, not readily explained by another cause.
Additional features that provided support for IRIS included:
temporal relationship with ART initiation (symptom onset
,3 months into ART); resolution without change in OI therapy;
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clinical course not consistent with pre-ART disease; no recent
cessation of therapy for a pre-existing condition; plausibility that
the antigen or pathogen was present prior to ART initiation;
unusual or florid presentation; and exclusion of other explanations
for the deterioration such as drug toxicity and drug-resistant
organisms.
Initial categorisation of events as IRIS or non-IRIS was done
without prior knowledge of ART response. When CD4 and viral
load data were subsequently available at the end of the study, we
considered that absence of any rise in the CD4 cell count
(610 cells) at clinical event or of a decline in the viral load
(60.25 log) made a diagnosis of IRIS unlikely, and such events
were therefore categorised as non-IRIS.
IRIS cases were classified according to mode of presentation
(paradoxical or unmasking) and underlying diagnosis (major OIs –
TB, WHO stage 4 conditions and viral hepatitis – or mucocuta-
neous if they affected primarily the skin, oropharynx or lower
genital tract). Therefore, the four subtypes of IRIS were:
paradoxical IRIS of major OIs (Paradox-OI), unmasking of major
OIs (Unmask-OI), paradoxical mucocutaneous IRIS (Paradox-
MC), and unmasking mucocutaneous IRIS (Unmask-MC). Possi-
ble and non-IRIS cases were categorised by underlying cause: new
infection; drug toxicity; progression of pre-ART disease; other
conditions. For recurrent condition such as genital herpes, we used
additional criteria to differentiate paradoxical IRIS from non-IRIS
recurrent disease: increased frequency and severity of recurrences,
and where relevant poor response to therapy, compared to pre-
ART.
Statistical analysis
Incidence rate and risk, time to event, and outcomes (death,
hospital admission, ART switch or interruption) were calculated
for each of the four IRIS subtypes and non-IRIS clinical events.
Patients at risk of paradoxical IRIS were those with a clinically
apparent OI or skin condition just prior to ART initiation
(regardless of prior serological evidence of infection). Patients at
risk of unmasking IRIS for a specific condition were those without
evidence of clinically active disease prior to ART. The de-
nominator for unmasking IRIS related to infections such as HSV-
2 and cryptococcosis was not restricted to those who were
seropositive. In this way, incidence calculations could be compared
with other studies and across all conditions. For non-IRIS clinical
events, the denominator was all patients in the cohort. Cox
proportional hazards models were used to identify risk factors for
each of the four IRIS subtypes, and hazard ratios (HR) were
estimated for each variable in univariate analyses, followed by
multivariable analyses of variables with P,0.10 in univariate
analyses. All adjusted HR (aHR), two-sided 95% confidence
intervals (CI) were calculated and graphs were plotted using
STATAH software version 10.
There were 4 groups of risk factors for development of IRIS (all
baseline unless stated): Patient related (e.g. age, sex, body mass index,
full blood count, renal and liver function); HIV-related (e.g. WHO
stage [not Paradox-OI], absolute and percentage baseline CD4+
and CD8+ counts, and log VL); ART-response associated (e.g. ART
drug regimen, CD4+ and VL response at 12 and 24 weeks); and
pathogen/disease-related (e.g. clinical and laboratory measures of
disease burden, such as CrAg titre, [clinical site and extent of
disease or quantitative measure; Paradox-OI only], extent of
disease on chest x-ray [Paradox-OI only], duration of prior OI
anti-infective therapy or prophylaxis prior to ART [Paradox-OI
only], C-reactive protein, number of previous OIs, current or
previous TB [MC-IRIS only], and systemic symptoms [cough,
weight loss, night sweats, fever], mucocutaneous symptoms
[extent, duration and severity of skin and orogenital lesions],
cryptococcal antigen (CrAg) positivity [OI IRIS only], and use of
co-trimoxazole and fluconazole prophylaxis prior to ART).
Results
Patient characteristics (Table 1)
Of 498 participants, at ART initiation 375 (75.3%) were female,
median age 35 years (interquartile range [IQR] 30–41 years),
median CD4+ count 106 cells/mL (53–165 cells/mL), median VL
5.0 log10 copies/mL (4.4–5.6 log10 copies/mL), 344 (69.1%)
WHO stage 3 or 4 disease, and 102 (20.5%) known TB co-
infection. 243 (48.8%) had a positive TB symptom score [36], of
whom 189 (77.8%) screened negative for active TB. Eight (1.6%)
had recent cryptococcosis, 7 (1.4%) had KS, 39 (7.8%) were
hepatitis B surface antigen positive, and 154 (30.9%) had a history
of genital ulcer disease. During 214 patient-years (PY) of follow-up,
25 (5.0%) died at a median 83 days after ART initiation (IQR 28–
107 days), and 21 (4.2%) were lost to follow-up. At 24 weeks, the
median CD4+ cell count had risen to 193 cells/mL (IQR 135–
270 cells/mL) and 343/423 (81.1%) patients remaining under
follow-up had VL ,50 copies/mL.
Incidence, clinical spectrum and timing of IRIS
Over the 24 weeks of follow-up, there were 620 clinical events,
of which 139 (22.4%) in 114 patients were considered probable
IRIS (cumulative incidence 22.9%; rate 64.8/100 PY [Table 2]).
An additional 111 (17.9%) initially considered possible IRIS were
subsequently considered non-IRIS as the preponderance of
evidence suggested IRIS was unlikely. Five events originally
classified as probable IRIS were excluded because of the absence
of any virological or immunological response at the time of the
event. Non-IRIS events accounted for the majority of post-ART
events and comprised 161 new infections (incidence 26.7%), 144
cases of pre-existing disease with relapse, progression or persis-
tence of symptoms (22.5%), 75 drug toxicities (14.1%), and 101
other problems (17.7%).
Figure 1 shows the clinical spectrum of IRIS according to mode
of presentation and underlying diagnosis. Overall, 89/139 IRIS
events (64.0%) were unmasking in presentation, and 50 (36.0%)
were paradoxical; 44 were related to major OIs (31.7%) and 95
(68.3%) were mucocutaneous. The commonest major OI associ-
ated with IRIS was TB (24.5% of all IRIS events; 15 paradoxical
and 19 unmasking), followed by cryptococcosis (2.9%; 2 paradox-
ical and 2 unmasking). Immune reconstitution folliculitis (IRF) was
the most frequent IRIS event overall (27.3%; 12 paradoxical and
26 unmasking), usually presenting as a pruritic, papular or pustular
eruption with a central distribution. Viral mucocutaneous IRIS
was also common (29.5%; 12 paradoxical and 29 unmasking), and
included genital herpes, herpes zoster, extragenital herpes simplex,
and warts.
Table 2 shows the incidence rate of different subgroups of IRIS.
Of 135 patients with a pre-existing OI, 18 (13.3%) developed
Paradox-OI IRIS, and the incidence was similar for TB (13.7%),
cryptococcosis (25.0%) and KS (14.3%), although with wide
confidence intervals for the latter two conditions. Of 322 patients
with a history of mucocutaneous disease at baseline, 30 (9.3%)
developed Paradox-MC IRIS, most frequently immune reconsti-
tution folliculitis (IRF) (8.5%), warts (7.9%), genital herpes simplex
(3.2%) and herpes zoster (2.4%). Out of 498 patients, 25 (5.0%)
developed Unmask-OI IRIS and 52 (10.4%) developed Unmask-
MC IRIS. The most common Unmask-OI IRIS events were TB
(incidence 4.8%), followed by cryptococcosis (0.4%), and the most
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common Unmask-MC IRIS events were IRF (7.3%), genital
herpes simplex (2.3%) and warts (1.5%).
Figure 2 shows the rapidly declining incidence rates of
paradoxical IRIS, unmasking IRIS, and non-IRIS clinical events
over 24 weeks after ART initiation. 99 (71.2%) and 123 (88.5%)
IRIS events occurred within the first 6 and 12 weeks after ART
initiation respectively, compared with 59.0% and 80.9% for non-
IRIS events. In the first 6 weeks, 25.5% of all events were due to
IRIS, compared to only 8% of events in weeks 19–24. The median
time to onset of IRIS after starting ART was 15 days (IQR 7–
48 days), compared to 27 days (IQR 7–66 days) for non-IRIS
events (p = 0.0048, Mann-Whitney test). Unmasking IRIS oc-
curred slightly later (median 21 days, IQR 7–52 days) than
paradoxical IRIS (11 days, IQR 7–24 days) (P= 0.043).
Table 1. Demographic, clinical and laboratory characteristics of 498 study participants at ART initiation.
Characteristic Median
Inter-quartile
range Number %
Age, years 34.5 29.4–40.5
Female 375 75.3
Body mass index (kg/m2) 23.2 20.5–27.1
WHO stage 1 67 13.5
2 88 17.7
3 280 56.2
4 63 12.7
OI history (in past year
unless stated)
Lifetime history of TB 220 44.2
Current TB, on anti-TB therapy 102 20.5
Duration of anti-TB therapy prior to ART (days) 81 56–152
Cryptococcosis * 8 1.6
Duration of current cryptococcosis therapy (days) 171 92–248
Kaposi’s sarcoma ** 7 1.4
Herpes zoster (last 5 years) 126 25.3
Genital ulcers 155 31.1
Any skin complaint 275 55.2
Folliculitis 142 28.5
Positive serology Hepatitis B surface antigen 39 7.8
Hepatitis C IgG 1 0.2
Syphilis RPR/TPHA 14 2.8
Cryptococcal antigen *** 41 8.2
Symptoms (at least 2
weeks)
Weight loss .10% 188 37.7
Night sweats 164 32.9
Fever 134 26.9
Cough 191 38.4
Positive tuberculosis symptom score **** 243 48.8
Unexplained diarrhoea $4 weeks 104 20.9
ART regimen Stavudine, lamivudine, and efavirenz 312 62.7
Stavudine, lamivudine, and nevirapine 186 37.3
Laboratory Haemoglobin (g/dL) 11.2 10.0–12.4
CD4+ count (cells/mL) 106 53–165
CD4+% 9 5–13
CD8+ count (cells/mL) 666 447–1039
CD8+% 63 54–72
Viral load (log10 copies/mL) 4.98 4.38–5.56
*All 8 cryptococcosis patients were receiving oral fluconazole maintenance treatment at ART initiation following induction therapy with amphotericin B (n=5) or high-
dose fluconazole (n= 3).
**Sites of Kaposi’s sarcoma (KS): oral (n= 4), cutaneous (n=2), or both (n=1). Only one patient had received KS-specific chemotherapy.
***8 (19.5%) of 41 serum CrAg positive patients identified from retrospective testing of baseline samples had a prior history of cryptococcal disease. The remainder were
asymptomatic at baseline, of whom 2 (6.1%) developed unmasking cryptococcal IRIS.
****Defined as the presence $2 of the following symptoms for $2 weeks: cough, fever, night sweats, weight loss.
ART: anti-retroviral therapy; CrAg: cryptococcal antigen; RPR: rapid plasma reagin; TB: tuberculosis; TPHA: Treponema pallidum haemagglutination assay.
doi:10.1371/journal.pone.0040623.t001
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Outcomes and impact of IRIS
Figure 3 shows the proportions of deaths, hospitalizations, ART
switches and ART interruptions that were attributed to IRIS,
compared to non-IRIS events. Non-IRIS events due to pro-
gression of pre-existing disease accounted for 23/65 (35%) hospital
admissions and 8/25 (32%) deaths. Drug toxicity was the most
common cause of ART switches (16/28; 57%) and interruptions
(6/13; 46%).
Of the 25 deaths, six (24%) were caused by IRIS (unmasking of
disseminated TB [n = 3], unmasking strongyloidiasis [n = 1],
paradoxical TB/cryptococcosis [n = 1] and paradoxical KS
[n = 1]). The 19 non-IRIS causes of death were: new infections
(pneumonia [n = 3], bacterial meningitis [n = 1], other septicaemia
[n = 2]); progression of pre-existing diseases (TB in a non-adherent
patient [n = 1], carcinoma of the cervix [n = 1], chronic diarrhoea
[n = 2], progressive cryptococcosis [n = 1], progressive demise of
unknown cause [n = 1]); and other causes (pulmonary embolus
[n = 2], suicide [n = 1], road traffic accident [n = 1], sudden death
of unknown cause at home [n = 3] of whom one was not adherent
to ART). Of the 65 hospital admissions, 13 (20%) were due to
IRIS events: unmasking TB-IRIS (n = 7), paradoxical TB-IRIS
(n = 2), cryptococcosis (n = 1), KS (n = 1), strongyloidiasis (n = 1),
and severe genital warts requiring surgery (n = 1). Of the 43
patients with IRIS related to major OIs, 16.3% died (compared to
7.0% of those with any IRIS type, and 7.0% with a non-IRIS
event) and 34.9% were hospitalised.
Thirteen (11.4%) patients with IRIS changed ART regimens,
although this was not significantly different from those without
Table 2. Incidence of IRIS and non-IRIS clinical events, and IRIS subtypes over the 24 weeks after ART initiation (n= 498 patients,
620 events).
Event
No.
events
Patients with
event/Patients
at risk
% incidence
(95% CI)
Onset of event,
median days after
starting ART (IQR)
Any IRIS 139 114/498 22.9 (19.3–26.8) 15 (7–48)
New infection * 161 133/498 26.7 (22.9–30.8) 52 (21–91)
Pre-existing disease (Relapse, progression or
persistent symptoms)
144 112/498 22.5 (18.8–26.2) 16 (7–42)
Drug toxicity 75 70/498 14.1 (11.1–17.4) 25 (7–69)
Other ** 101 88/498 17.7 (14.3–21.0) 24 (7–62)
Paradoxical OI IRIS All major OIs 19 18/135 13.3 (8.1–20.3) 10 (7–21)
Tuberculosis 15 14/102 13.7 (7.7–22.0) 10 (7–21)
Cryptococcosis 2 2/8 25.0 (3.2–65.1)
Kaposi’s sarcoma 1 1/7 14.3 (0.4–57.9)
Oesophagitis 1 1/21 4.8 (0.1–23.8)
Unmasking OI IRIS All major OIs 25 25/498 5.0 (3.3–7.3) 12 (7–46)
Tuberculosis 19 19/396 4.8 (2.9–7.4) 12 (7–49)
Cryptococcosis 2 2/490 0.4 (0.05–1.5)
Kaposi’s sarcoma 0 0/491 0
Other major OI *** 4 4/498 0.8 (0.2–2.0)
Paradoxical mucocutaneous
IRIS
All mucocutaneous
conditions
31 30/322 9.3 (6.4–13.0) 14 (7–28)
Folliculitis 12 12/142 8.5 (4.4–14.3) 7 (7–21)
Warts 3 3/38 7.9 (1.7–21.4)
Genital herpes simplex 5 5/155 3.2 (1.1–7.4)
Herpes zoster 3 3/126 2.4 (0.5–6.8)
Unmasking mucocutaneou
IRIS
All mucocutaneous
conditions
64 52/498 10.4 (7.9–13.5) 23 (7–53)
Folliculitis 26 26/356 7.3 (4.8–10.5) 38 (9–58)
Warts 7 7/460 1.5 (0.6–3.1)
Genital herpes simplex 8 8/343 2.3 (1.0–4.5)
Herpes zoster 6 6/372 1.6 (0.6–3.5)
The denominators for paradoxical IRIS relating to each opportunistic condition were defined by the number of patients with clinically apparent disease at or just prior to
ART initiation. In contrast, patients at risk of unmasking IRIS were those without clinically apparent disease prior to ART. For non-IRIS clinical events, the denominator
was the total number of patients in the cohort. (n= 498). ART: anti-retroviral therapy; CI: confidence interval; IQR: interquartile range; IRF: immune reconstitution
folliculitis; IRIS: immune reconstitution inflammatory syndrome; OI: opportunistic infection; PY: patient-years.
*Most common new non-IRIS infections were: upper or lower respiratory tract infection (n= 53); skin infections (fungal [n= 14], bacterial [n= 8] or other [n=8]); enteric
infection (n=21); vaginal infection (n= 20); other genitourinary infections (n= 12); sepsis/bacteraemia (n= 5).
**Most common ‘‘other’’ non-IRIS events were: skin conditions (n= 21); non-specific constitutional symptoms and headache (n= 19); arthropathy/musculoskeletal
problems (n=16); genitourinary conditions (n=14); gastrointestinal complaints (n= 10); trauma (n= 6). For arthropathy, alternative explanations included: trauma;
arthralgia associated with a non-specific viral infection; pyrazinamide toxicity; myalgia and arthralgia without any signs or apparent aetiology.
***Includes one case each of oesophagitis, strongyloidiasis, sarcoidosis and non-tuberculous mycobacterial infection.
doi:10.1371/journal.pone.0040623.t002
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IRIS (6.4%, P= 0.11). All IRIS-related changes in ART were due
to initiation of rifampicin as part of TB therapy, requiring a switch
from nevirapine to efavirenz. IRIS had no apparent impact on
adherence to ART, with a similar proportion of patients with or
without IRIS having .95% adherence based on pill counts at
every study visit.
Risk factors for IRIS
In multivariable analysis, statistically significant risk factors for
Paradox-OI IRIS (Figure 4a) were baseline VL .5.5 vs.
,4.5 log10 copies/mL (aHR 7.23, 95% CI 1.35–38.76,
P= 0.021) and #30 vs. .30 days of OI therapy (mainly TB)
prior to ART (aHR 2.66, CI 1.16–6.09, P= 0.021). When
analysed as a continuous variable, for each 1 log10 copies/mL
increase in VL there was a 2.48-fold increased hazard (CI 1.43–
4.31, P= 0.001). Additional risk factors of borderline statistical
significance in univariate but not multivariable analyses were BMI
,20 vs. $20 kg/m2 (crude HR 2.32, CI 0.94–5.70, P= 0.068;
aHR 1.93, CI 0.82–4.56, P= 0.13), pre-ART CD4+ count #50 vs.
.100 cells/mL (crude HR 3.51, CI 0.95–12.96, P= 0.060; aHR
2.23, CI 0.61–8.10, P= 0.22), and pre-ART CD4+ count 51–100
vs. .100 cells/mL (crude HR 3.75, CI 0.97–14.50, P= 0.056;
aHR 3.33, CI 0.85–13.10, P= 0.085).
Risk factors for Unmask-OI IRIS on multivariable analysis
(Figure 4b) were evidence of lymphadenopathy vs. no lymphade-
nopathy on pre-ART chest x-ray (aHR 9.15, CI 4.10–20.42,
P,0.001), haemoglobin ,10 vs. .12 g/dL (aHR 3.36, CI 1.32–
8.52, P= 0.011); CRP $25 vs. ,25 mg/L (aHR 2.77, CI 1.31–
5.85, P= 0.008), and $10% vs. ,10% weight loss prior to ART
(aHR 2.31, CI 1.05–5.11, P= 0.038). A positive TB symptom
score [36] was less predictive of IRIS than weight loss alone (one of
the four components of the score) (aHR 2.23, CI 0.95–5.24,
P= 0.066).
There were no statistically significant risk factors for Paradox-
MC IRIS in multivariable analysis (Figure 4c). However, on
univariate analyses, a baseline CD4+ count of#50 vs..100 cells/
mL was predictive (crude HR 1.90, CI 1.26–6.63, P= 0.012; aHR
1.97, CI 0.81–4.81, P= 0.14) and a CD4+ count of 51–100 cells/
mL was of borderline significance (crude HR 2.25, CI 0.91–5.60,
P= 0.081; aHR 1.60, CI 0.61–4.20, P= 0.34). When analysed as
a continuous variable, each 50 cell decline in CD4+ count was
associated with a 1.4-fold increased hazard (CI 1.06–1.84,
P= 0.018). The nature, distribution and duration of pre-ART
Figure 1. Clinical spectrum of 139 IRIS events by mode of presentation (paradoxical or unmasking) and underlying diagnosis. *
Features of oesophagitis IRIS were odynophagia with significant anorexia, endoscopic findings, or haematemesis, with a clinical course consistent
with paradoxical or unmasking IRIS and not typical of reflux or other common causes. ** The strongyloides IRIS case was unusual in its severity (it was
diagnosed post mortem); the arguments that this case was IRIS have been published in a case report [67]. *** Based on clinical evidence of genital
ulcer disease (GUD), pre-ART serologic evidence of herpes simplex virus (HSV)-2 infection, and exclusion of syphilis or confirmation of HSV-2 by
polymerase chain reaction on ulcer swab. A diagnosis of unmasking HSV-IRIS was based on new onset GUD despite pre-ART serologic evidence of
herpes simplex virus (HSV)-2 infection. A diagnosis of paradoxical HSV-IRIS was based on increasing frequency and/or severity of episodes of known
recurrent genital herpes, relative to pre-ART. Anti-herpetic therapy was not available in this setting. **** Genital, orolabial or generalised warts.
Unmasking IRIS involving genital warts was supported by a history of sexual abstinence since prior to ART initiation. ***** Intra-oral pain and
ulceration (n = 6), or extra-oral ulceration (n = 3, one involving most of the face), with virological confirmation of HSV-1 by polymerase chain reaction,
or no other likely causative organism. ****** Features suggestive of tinea IRIS were: unusually rapid spread of lesions, or marked inflammation. There
were 18 more ‘‘typical’’ non-IRIS tinea cases that occurred during an interruption in ART, or where clinical history was insufficient to support an IRIS
diagnosis.
doi:10.1371/journal.pone.0040623.g001
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mucocutaneous conditions were not associated with subsequent
paradoxical IRIS.
Risk factors for Unmask-MC IRIS on multivariable analysis
(Figure 4d) were current TB (aHR 2.00, CI 1.02–3.93, P= 0.045)
and previous TB (aHR 2.30, CI 1.21–4.37, P= 0.011), vs. those
with no history of TB, mild anaemia of Hb 10–12 vs. .12 g/dL
(aHR 1.98, CI 1.04–3.78, P= 0.037), but not Hb ,10 g/dL, and
use of co-trimoxazole for at least one month prior to ART vs.
starting co-trimoxazole concurrently with ART (aHR 1.97, CI
1.06–3.65, P= 0.032). Of note, when possible and probable IRIS
were combined, there was a similar magnitude of effect for the
various risk factors for all IRIS subtypes, but the confidence
intervals were wider.
Figure 2. Rate of IRIS and non-IRIS events over 24 weeks from anti-retroviral therapy (ART). Rates are calculated per 100 patient-years
(PY) in 3-week intervals, with 95% confidence intervals. Separate plots are shown for paradoxical IRIS (m), unmasking IRIS (N) and non-IRIS events (6).
Rate of non-IRIS events in the first 3 weeks was 741 events/100 PY (95% confidence interval 648–848) (data not plotted).
doi:10.1371/journal.pone.0040623.g002
Figure 3. Major adverse outcomes within 24 weeks of starting antiretroviral therapy, with underlying cause.
doi:10.1371/journal.pone.0040623.g003
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Discussion
This large cohort study of 498 patients initiating ART in
Durban, South Africa provides the most comprehensive evidence
to date on the frequency, clinical spectrum, timing, outcome, and
programmatic impact of IRIS relative to other clinical events
following ART initiation in a sub-Saharan African setting.
Particular strengths of our study include the prospective data
collection, rigorous ascertainment and assessment of all clinical
events, a standardised approach to defining IRIS with inclusion of
cases at the milder end of the spectrum of IRIS, and differentiation
between paradoxical and unmasking IRIS events and between OIs
and less serious conditions.
In this study, the cumulative incidence of IRIS was 22.9%, or
65 cases per 100 PY, of which 64% were unmasking and 36%
paradoxical. The incidence rates of the different IRIS subtypes
were: paradoxical major OI, 13.3% of patients with an existing OI
at the time of ART initiation; unmasking major OI, 5.0% of the
entire cohort; paradoxical mucocutaneous, 9.3% of patients with
relevant pre-existing conditions; and unmasking mucocutaneous,
10.4% of the entire cohort. One quarter of all IRIS events were
due to TB, with other OIs accounting for only 10 cases (7%). The
remaining 68% of IRIS events were due to mucocutaneous
conditions, mainly immune reconstitution folliculitis, a well-
recognised but poorly quantified IRIS phenomenon [37,38,39],
followed by viral skin conditions such as herpes simplex, warts and
herpes zoster.
Our overall IRIS rate and clinical spectrum is comparable to
a London cohort of predominantly black African patients [2],
which reported 22.7% cumulative incidence (20% due to major
OIs or HBV, and 80% to dermatological conditions), but higher
than the 10–17% reported from studies in other RLS [1,4,5]. This
may be partly explained by the low ascertainment of mucocuta-
neous IRIS events in these studies, lower rates of paradoxical TB-
IRIS [1] and possible missed ascertainment of early IRIS events
due to death or loss to follow-up (median IRIS onset 48 days
compared to 15 days in our study). Our observed 4.8% incidence
of unmasking TB-IRIS and combined 0.8% incidence of
unmasking and paradoxical cryptococcal IRIS were similar to
those reported in studies from other RLS for TB (3.7–5.9%)
[1,25,40] and cryptococcal disease (0.3–1.6%) [19]. The incidence
of mucocutaneous IRIS (19.1%) was more consistent with results
from retrospective studies conducted in higher income settings (9–
20% [2,3,6]) than in RLS (2–8% [1,4,5]).
The wide range of incidence of IRIS reported across studies
may be explained by variations in patient-, site- and setting-
specific factors [41], quality of screening prior to ART, or by case
ascertainment and definition methods. Comparisons across studies
are further constrained by the failure in most studies to
discriminate between paradoxical and unmasking presentations,
and the lack of a standardised case definition for IRIS. In the
absence of clear immunopathological correlates or diagnostic
assays, the differentiation of IRIS from other competing diagnoses
and particularly unmasking IRIS from a new infection, or
paradoxical IRIS from natural history of pre-existing disease,
remains challenging. While no single case definition can compre-
hensively address all possible presentations of IRIS, the progressive
development and use of both generic [10,27,42] and pathogen-
specific [9,19] case definitions in this and future studies of IRIS
will improve reliability and comparability across studies.
We also evaluated the relative importance of IRIS compared to
early non-IRIS clinical events. IRIS accounted for almost one
quarter of all clinical events and deaths and one fifth of
hospitalisations in the initial 24 weeks after ART initiation, which
was similar to the contribution of non-IRIS new infections. Of the
114 patients who developed any type of IRIS event, 7% died,
similar to the IRIS mortality of 5% and 9% reported in two studies
from RLS [1,5]. However, among the subgroup of patients with
IRIS related to major OIs, there was a much higher morbidity and
mortality (16.3% died, 34.9% were hospitalised, and 4.7%
discontinued ART). Overall, there was no apparent negative
impact of IRIS on ART adherence and retention, although follow-
up was more intensive in our study than would be usual in most
settings. Drug toxicity accounted for few events or hospitalisations,
and no deaths, but almost half of ART discontinuations and
regimen changes.
The baseline characteristics of our study population (pre-
dominantly young, female, with a high prevalence of WHO stage
3–4 disease and very low baseline CD4+ counts) are typical of
other high HIV prevalence settings in sub-Saharan Africa
[1,5,43,44,45,46,47,48,49]. We therefore extrapolated our find-
ings to estimate the wider programmatic impact of IRIS. By 2009,
approximately 972,000 patients had initiated ART in South Africa
[50]. Assuming a 5% incidence of unmasking OI-IRIS, a 20%
prevalence of co-infection with major OIs at ART initiation, a 13%
incidence of paradoxical IRIS, and case fatality and hospitalisation
rates of major OI-IRIS of 13.6% and 27.3%, we estimate that
IRIS may have caused around 10,000 deaths and 20,000 hospital
admissions in the South African ART programme alone since
inception. If we apply the same assumptions to the 2.2 million
individuals who have initiated ART across the ten countries with
the largest ART programmes, IRIS may have accounted for as
many as 23,000 deaths in these countries. The impact of IRIS is
likely to increase as ART programmes in Africa are integrated
with inpatient services, and ART is increasingly offered to those
with major OIs and more advanced disease. However, it is
important to emphasise that the effects of IRIS were similar to the
number of events, deaths and hospitalisations caused by new non-
IRIS infections, but slightly less than those caused by pre-existing
conditions.
We identified some important differences in risk factor profiles
between paradoxical and unmasking, and major OI-associated
and mucocutaneous IRIS, consistent with these being distinct
entities with differing pathogenesis, although these subgroup
analyses were limited by small numbers. Consistent with previous
studies, lower CD4+ count [1,2,3,7,16,18,26] and higher VL
[3,15,30] at baseline were predictors of paradoxical OI (mainly
TB)-IRIS, but not unmasking IRIS, together with shorter period
of pre-ART duration of OI/TB therapy OI-IRIS
[13,16,28,29,30,31,51], which is likely to be related to a higher
residual pathogen load. In contrast with several published studies,
the magnitude and rate of CD4+ immune reconstitution
[6,15,32,33] and VL reduction following ART initiation
[13,26,28,33] were not predictive of any type of IRIS. However,
comparison across studies is difficult because of the potential
confounding effect of a low baseline CD4+ count, and the use of
Figure 4. Multivariable analysis of risk factors for IRIS according to subtype. A, paradoxical IRIS related to major OIs (19 events in 135
patients [n= 15 TB]); B, unmasking IRIS related to major OIs (25 events in 498 patients [n= 19 TB]); C, paradoxical mucocutaneous IRIS (31 events in
418 patients); D, unmasking mucocutaneous IRIS (64 events in 498 patients). All variables were pre-ART unless stated. Potential risk factors were
excluded from multivariable models if P$0.10 on univariate analysis. LN: lymphadenopathy; OI: opportunistic infection.
doi:10.1371/journal.pone.0040623.g004
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CD4+ and VL responses in defining IRIS in some studies
[6,13,15,26,28,32].
For unmasking OI (predominantly TB) IRIS, the risk factors we
identified were all consistent with the presence of sub-clinical
disease, in particular lymphadenopathy present on chest X-ray,
low haemoglobin, greater than 10% weight loss, and high baseline
CRP. All were associated with at least a two- to three-fold
increased risk of IRIS, and in the case of lymphadenopathy, a nine-
fold risk. There are few existing data on risk factors for unmasking
IRIS. One recent small study from Uganda of unmasking TB-
IRIS identified both a low BMI and high CRP as independent
predictors [25], but an Indian study identified no specific risk
factors [51]. This is the first study to examine risk factors specific
for mucocutaneous IRIS – the most common type of IRIS. Not
surprisingly, with such a diverse range of conditions encompassing
viral and bacterial aetiologies, identification of common risk
factors was less productive. A low baseline CD4+ count was weakly
predictive of paradoxical MC IRIS, and mild anaemia and
a history of current or past TB were associated with unmasking
MC IRIS.
There are several practical implications of our findings for
reducing IRIS-associated morbidity and mortality in ART
programmes. First, earlier HIV diagnosis and initiation of ART
in accordance with revised WHO guidelines at a CD4+ count of
350 cells, and certainly before a decline to below 200 cells,
remains the most important strategy to reduce the prevalence of
major OIs, and the incidence of most serious and life-threatening
IRIS and non-IRIS events. We estimate that for each 50 cell
increase in baseline CD4 count at ART initiation, there would be
a 17% reduction in the risk of any IRIS (95% CI 6–26%), and
a 43% reduction in all-cause mortality (95% CI 19–60%).
Second, to reduce the likelihood of paradoxical OI IRIS, there
is a need to optimise pre-ART OI management and timing of
ART. Consistent with other reports, we found that a shorter
duration of pre-ART OI/TB therapy was predictive of OI-IRIS
[13,16,28,29,30,31,51], which is likely to be related to a higher
residual pathogen load. The optimal timing of ART in patients
with OIs requires balancing greater risk of IRIS after early
initiation against continuing high mortality with delayed ART.
Several RCTs of TB show a mortality benefit from earlier ART in
TB [52,53,54], while one RCT suggested a benefit of deferral for
ten weeks with cryptococcal infection [55]. While there are
limitations in using observational data to inform this debate, our
data can be viewed in conjunction with these RCTs and other
IRIS cohort studies.
Third, there is a need to improve screening for OIs, particularly
TB and cryptococcus, prior to ART initiation, to reduce the
development of unmasking IRIS of major OIs, which are
associated with a particularly poor outcome [46,56,57]. Several
features suggestive of sub-clinical TB were predictive for
unmasking TB in our study, suggesting that existing practices for
pre-ART screening and treatment are inadequate. HIV pro-
grammes in high TB prevalence settings should incorporate
a simple validated symptom score [36,58] (with additional chest x-
ray and sputum examination as required) into routine pre-ART
evaluation, as recommended in WHO 2010 guidelines on
intensified case finding [59]. This will be further enhanced by
the increasing availability of rapid point of care tests for TB
diagnosis [60]. Screening for cryptococcal antigen prior to ART
initiation in patients with a CD4+ count less than 100 cells with
pre-emptive fluconazole treatment in those who are serum CrAg
positive has been shown to be a cost-effective intervention to
reduce mortality [61,62,63] and this is now a recommendation for
high cryptococcal prevalence settings in recent WHO advice [64].
Further operational research is needed to determine the feasibility
and impact of a serum CrAg ‘‘screen and treat’’ strategy [65,66].
More intensive monitoring of selected patients at high risk of
IRIS (e.g. CD4+ count ,50 cells, known OI, unexplained
symptoms) in the initial few weeks after starting ART is a further
strategy to reduce IRIS-related mortality by facilitating prompt
management of severe IRIS. IRIS is generally self-limiting and
interruption of ART is rarely indicated, but patients may require
reassurance in the face of protracted symptoms to prevent
discontinuation of or poor adherence to ART. Few national
HIV guidelines from RLS contain guidance on recognition and
management of IRIS. There is a need for both better health care
worker training in this area as well as improved patient awareness.
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